Incyte Corp
1 products tracked · names used in filings: Incyte Corp
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Fri 01 May 2026🇺🇸 FDA approval
FDA approves Jakafi Xr (ruxolitinib phosphate): new formulation or manufacturer
Incyte Corp; NDA217180; New formulation or manufacturer; tablet, extended release · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇺🇸 | Jakafi Xr ruxolitinib phosphate | Approved | 2026-05-01 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.